



Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021

March 12, 2021 at 7:00 AM EST

DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Investor Contact:

Alex Kelly
Interim Chief Financial Officer
Alex.Kelly@precisionbiosciences.com

Media Contact:

Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com